ADMET analysis predicted a favorable safety profile over sorafenib, particularly with respect to carcinogenic and chronic toxicity risks. These findings indicate that quinoxaline derivative 11d holds potential as a selective and effective VEGFR-2 inhibitor with promising antitumor and anti-metastatic properties, warranting further investigation.
INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) is a well-established therapeutic target in cancer treatment. In this study, a novel N-phenylacetamide derivative of theobromine, designated as T-1-PA, was designed as a potential semisynthetic EGFR inhibitor. METHOD: The 3D structure, stability, and electronic reactivity of T-1-PA were determined using Density Functional Theory (DFT) analyses. Molecular docking, molecular dynamics (MD) simulations, Molecular Mechanics Generalized Born Surface Area (MM-GBSA), Protein-Ligand Interaction Profiler (PLIP), and Principal Component Analysis of Trajectories (PCAT) were employed to evaluate the binding affinity and inhibitory potential of T-1-PA against EGFR. Computational ADMET profiling was conducted to predict drug-likeness and safety. Subsequently, T-1-PA was semisynthesized and subjected to in vitro biological evaluation. RESULTS: Computational analyses demonstrated a strong binding affinity of T-1-PA to EGFR. The compound exhibited favorable ADMET properties. In vitro assays revealed potent EGFR inhibition with an IC₅₀ of 0.736 ± 0.005 μM. T-1-PA also inhibited the proliferation of HepG2 and MCF7 cancer cell lines with IC₅₀ values of 0.88 ± 0.01 μM and 1.13 ± 0.01 μM, respectively. Flow cytometry analysis indicated induction of apoptosis and G1 phase cell cycle arrest in HepG2 cells. Additionally, T-1-PA significantly impaired HepG2 cell migration and wound-healing capacity. DISCUSSION: The results validate the computational predictions and highlight the anticancer potential of T-1-PA through EGFR inhibition and antiproliferative activity. The compound's favorable pharmacokinetic and safety profiles further support its therapeutic promise. CONCLUSION: T-1-PA is a promising semisynthetic compound with selective antiproliferative activity mediated via EGFR inhibition. These findings encourage further preclinical investigation of T-1-PA as a novel candidate for EGFR-targeted cancer therapy.
Background Thiadiazole-sulfonamide derivatives were synthesized as dual inhibitors of epidermal growth factor receptor (EGFR) and carbonic anhydrase IX (CA-IX) to develop selective anticancer agents.Methods Cytotoxicity was evaluated against MDA-MB-231 and MCF-7 breast cancer cells, with selectivity tested on Vero cells. Enzymatic inhibition studies were conducted against EGFR and CA-IX, using erlotinib and acetazolamide as reference drugs. Apoptosis was assessed through gene expression analysis of BAX/Bcl-2, caspase-8, and caspase-9, alongside flow cytometry for apoptosis and cell cycle analysis. Molecular docking and 200 ns molecular dynamics (MD) simulations evaluated binding interactions. Density Functional Theory (DFT) calculations and in silico ADMET predictions assessed stability, electronic properties, and safety.Results Compound 14 exhibited potent cytotoxicity (IC₅₀ = 5.78 μM, MDA-MB-231; 8.05 μM, MCF-7) and high selectivity (IC₅₀ = 313.08 μM, Vero). It inhibited EGFR (IC₅₀ = 5.92 nM) and CA-IX (IC₅₀ = 63 nM), surpassing reference drugs. Apoptosis induction was confirmed by a 13.97-fold increase in BAX/Bcl-2, caspase upregulation, and G1-phase arrest. Computational analyses confirmed stable binding and favorable safety.Conclusions Compound 14 represents a promising dual EGFR/CA-IX inhibitor with selective anticancer activity. Further in vivo studies are warranted.
EGFR inhibitorscarbonic anhydrase IX inhibitorsanticancer agentsbreast cancer
Aims This study aimed to synthesize and evaluate novel furan derivatives as potential anticancer agents targeting colon cancer through VEGFR-2 inhibition and apoptosis induction.Materials and methods The cytotoxic activity of the synthesized compounds was assessed against human fibroblast (HSF) and colon cancer cell lines (HCT-116, Caco-2, and HT-29) using the MTT assay. VEGFR-2 inhibitory activity was determined in vitro, and immunocytochemistry was employed to evaluate VEGFR-2 expression. Apoptosis, cell cycle arrest, and migration inhibition were analyzed in Caco-2 cells. Molecular docking, molecular dynamics (MD) simulations, Density Functional Theory (DFT), and ADMET analyses were conducted to assess binding affinity, stability, and safety profiles.Results Compound 6 exhibited potent cytotoxicity against HT-29 (IC50 = 22.39 μM) and strong VEGFR-2 inhibition (IC50 = 0.28 ± 0.42 μM), comparable to sorafenib. It suppressed VEGFR-2 expression, induced G2/M cell cycle arrest, and promoted early and late apoptosis in 97% of treated Caco-2 cells. Upregulation of Bax and caspase-3, along with downregulation of Bcl-2, confirmed intrinsic apoptotic activation. Computational analyses supported compound 6’s stability and drug-likeness.Conclusions Compound 6 is a promising lead furan derivative with potent, selective anticancer activity against colon cancer via VEGFR-2 inhibition and apoptosis induction. Further, in vivo evaluation is warranted.
Abstract In this study, a series of nicotinamide‐dihydrothiadiazole hybrids were synthesized and evaluated for their anticancer potential through VEGFR‐2 inhibition. Among the synthesized compounds, 7c demonstrated a very promising VEGFR‐2 inhibitory activity (IC₅₀ = 0.098 ± 0.05 µM), comparable to the reference drug sorafenib (IC₅₀ = 0.1 ± 0.05 µM). In vitro cytotoxicity studies revealed that 7c exhibited significant anticancer activity against MDA‐MB‐231 (IC₅₀ = 6.92 ± 0.4 µM) and MCF‐7 (IC₅₀ = 9.18 ± 0.7 µM) breast cancer cell lines, with minimal toxicity toward normal cells (WI‐38 and WISH). Mechanistic studies indicated that 7c induces G0/G1 phase arrest and apoptosis, as evidenced by increased late apoptotic populations (45.58%) and upregulation of caspase‐3, Bax, and a significant reduction in Bcl‐2. Computational analyses, encompassing molecular docking and 200 ns molecular dynamics (MD) simulations, demonstrated the stable interaction of 7c with VEGFR‐2, highlighting its excellent binding affinity. Additionally, Swiss ADMET predictions highlighted the favorable pharmacokinetic and safety profiles of 7c , including non‐mutagenic and noncarcinogenic properties, moderate absorption, and high plasma protein binding (>90%). These findings establish nicotinamid‐dihydrothiadiazole hybrids, particularly 7c , as promising VEGFR‐2 inhibitors with dual mechanisms of angiogenesis inhibition and apoptosis induction.
mechanistic studies further confirmed the activation of the intrinsic apoptotic pathway, as evidenced by caspase-3 activation (8.2-fold), Bax upregulation (6.9-fold), and Bcl-2 downregulation (3.68-fold). Computational studies, including molecular docking and 200 ns molecular dynamics (MD) simulations, confirmed the stable interaction of 7a with VEGFR-2, showing binding affinities comparable to sorafenib. Further validation through MM-GBSA, ProLIF, PCAT, and FEL analyses reinforced its strong binding capability. Additionally, ADMET predictions suggested favorable pharmacokinetic properties, including good absorption, high plasma protein binding, and non-CYP2D6 inhibition. Moreover, toxicity analysis classified 7a as non-mutagenic and non-carcinogenic, with a lower predicted toxicity than sorafenib. Finally, density functional theory (DFT) calculations highlighted the structural stability and reactivity of 7a, further supporting its potential as a VEGFR-2 inhibitor. These findings suggest that 7a is a promising VEGFR-2 inhibitor with significant anticancer potential, favorable pharmacokinetics, and an improved safety profile. Further preclinical studies and structural modifications are warranted to optimize its therapeutic potential.
The co-expression of epidermal growth factor receptor and carbonic anhydrase-IX in aggressive tumors such as triple-negative breast cancer contributes to therapeutic resistance through proliferative signaling and hypoxia-mediated adaptation. Dual inhibition of these targets represents a promising strategy for overcoming tumor resilience and enhancing treatment efficacy. A novel thiadiazole-based hybrid molecule ( N -(4-(( E )-1-((( Z )-5-acetyl-3-(4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3 H )-ylidene)hydrazono)ethyl)phenyl)benzamide), ASTPB, was rationally designed through pharmacophore modeling, followed by molecular docking and molecular dynamics simulations for 200 ns to assess its dual-binding affinity to epidermal growth factor receptor and carbonic anhydrase-IX. Molecular dynamics simulations confirmed the stability of ASTPB complexes with both epidermal growth factor receptor and carbonic anhydrase-IX, as indicated by stable root mean square deviation values, consistent radius of gyration, and persistent hydrogen bonding, which supported its strong dual-binding affinity. Further quantum chemical analysis via density functional theory supported the electronic stability and reactive potential of ASTPB. In addition, in silico ADMET (Absorption, Distribution, Metabolism, Excretion, and toxicity) predictions indicated low toxicity, a wide safety margin, limited solubility and absorption, and overall favorable metabolic and distribution profiles. ASTPB was synthesized and exhibited potent dual inhibition of carbonic anhydrase-IX and epidermal growth factor receptor, with IC₅₀ values of 0.046 ± 0.007 µM and 0.059 ± 0.009 µM, respectively, comparable to standard inhibitors. In cytotoxicity assays, ASTPB was examined across several cancer cell lines (HePG-2, MCF-7, HCT-116, PC-3, MDA-MB-231), with the greatest efficacy against MDA-MB-231 (IC₅₀ = 18.15 µM) and minimal toxicity toward normal WI-38 cells (IC₅₀ = 72.46 µM). Cell cycle analysis revealed G0/G1 phase arrest, while Annexin V/PI staining indicated early apoptosis in 76.7% of cells. Molecular assays confirmed upregulation of Bax and caspase-3 (3.7-fold each) and downregulation of Bcl-2 (1.97-fold), indicating activation of the intrinsic apoptotic pathway. In conclusion, ASTPB is a promising dual carbonic anhydrase-IX/epidermal growth factor receptor inhibitor with selective cytotoxicity and potent pro-apoptotic activity, particularly in triple-negative breast cancer models. These findings support its potential as a multi-targeted therapeutic lead in the treatment of hypoxia-adapted, epidermal growth factor receptor–driven malignancies.
carbonic anhydrase IXepidermal growth factor receptortriple-negative breast cancerpharmacophore modeling
Chemical Biology & Drug Design · مجلد 106 (1) · e70156-e70156
ABSTRACT A new group of thiadiazole‐benzenesulfonamide hybrids was designed, synthesized, and biologically evaluated as potential dual inhibitors targeting B‐Raf and VEGFR‐2 for cancer therapy. The cytotoxic activity of the synthesized derivatives was assessed against HepG2 and Huh7 liver cancer cell lines, where compound 7a exhibited the most potent activity with IC 50 values of 17.89 μM and 25.07 μM, respectively. The kinase inhibition assay revealed that 7a strongly inhibited both B‐Raf (IC 50 = 0.11 μM) and VEGFR‐2 (IC 50 = 0.15 μM), surpassing sorafenib in B‐Raf inhibition. Further mechanistic studies revealed that 7a induced G2/M phase arrest, with a significant increase in late apoptotic cells (57.08%) compared to the control group (0.15%), confirming its pro‐apoptotic effect. The apoptotic pathway was further validated by caspase‐3 activation, Bax upregulation, and Bcl‐2 downregulation. Computational analyses verified the effective binding of compound 7a to VEGFR‐2. These analyses included molecular docking, molecular dynamic (MD) simulations, molecular mechanics with generalized Born and surface area solvation (MM‐GBSA), protein‐ligand interaction fingerprints (ProLIF), principal component analysis (PCAT), and free energy landscape (FEL) studies. Additionally, DFT studies indicated 7a 's stability and reactivity. In silico ADMET predictions indicated that the derivatives had good absorption, were non‐mutagenic, non‐carcinogenic, and exhibited low toxicity risks compared to sorafenib. These findings suggest that the synthesized thiadiazole‐benzenesulfonamide hybrids, particularly 7a , represent promising dual BRAF/VEGFR‐2 inhibitors with potent anti‐cancer activity, warranting further optimization and preclinical evaluation.
BRAF inhibitorsVEGFR-2 inhibitorsdual kinase inhibitorsliver cancer
Background Thieno-pyrimidine derivatives have emerged as promising candidates for VEGFR-2 inhibition. This study aimed to design, synthesize, and evaluate novel thieno-pyrimidine derivatives for their anti-cancer potential.Methods A series of thieno-pyrimidine compounds were synthesized and screened for in vitro cytotoxicity against MDA-231 and MCF-7 cell lines. The most active compound, 6b, was further analyzed for VEGFR-2 kinase inhibition, wound healing, apoptosis induction, and cell cycle arrest. Molecular docking, 200 ns molecular dynamics simulations, MM-GBSA, ProLIF PCAT, and FEL analyses were conducted to assess binding stability. DFT calculations evaluated electronic properties, while in silico ADMET profiling predicted pharmacokinetics and toxicity.Results Compound 6b exhibited potent cytotoxicity with IC50 values of 5.91 µM (MDA-231) and 7.16 µM (MCF-7). It demonstrated VEGFR-2 inhibition is comparable to sorafenib (IC50: 53.63 ± 3.14 nM). Wound healing assays showed significant inhibition of MDA-231 migration. Flow cytometry confirmed apoptosis induction (57.20% early apoptosis) and G1 phase arrest. Gene expression analysis revealed upregulation of pro-apoptotic markers and downregulation of Bcl-2. Computational studies confirmed stable VEGFR-2 binding, and ADMET predictions indicated a favorable safety profile.Conclusion Compound 6b exhibits strong VEGFR-2 inhibition, potent anti-cancer effects, and a favorable toxicity profile, highlighting its potential for further therapeutic development.
This study presents T-1-NBAB, a new compound derived from the natural xanthine alkaloid theobromine, aimed at inhibiting VEGFR-2, a crucial protein in angiogenesis. T-1-NBAB's potential to interacts with and inhibit the VEGFR-2 was indicated using in silico techniques like molecular docking, MD simulations, MM-GBSA, PLIP, essential dynamics, and bi-dimensional projection experiments. DFT experiments was utilized also to study the structural and electrostatic properties of T-1-NBAB. Computational analysis was performed to predict the ADME-Tox profiles of T-1-NBAB. After semisynthesis, the in vitro results showed that T-1-NBAB effectively inhibits VEGFR-2, with an IC50 of 0.115 μM, compared to sorafenib's 0.0591 μM. In vitro tests also demonstrated significant activity of T-1-NBAB against breast cancer cell lines MCF7 and T47D, with IC50 values of 16.88 μM and 61.17 μM, respectively, and high selectivity. Importantly, T-1-NBAB induced early and late apoptosis in MCF7 cells, indicating its potential as a strong anticancer agent. Additionally, T-1-NBAB reduced the migration and healing abilities of MCF7 cells, suggesting it could be a promising anti-angiogenic agent. Overall, these findings suggest that T-1-NBAB is a promising lead compound for further research as a potential treatment for breast cancer.
Journal of Computational Biophysics and Chemistry · مجلد 25 (11) · 2043-2063
Angiogenesis plays a pivotal role in tumor progression, and VEGFR-2 is a well-established therapeutic target in cancer treatment. In this study, we report the design, semi-synthesis, and comprehensive evaluation of a novel theobromine-based VEGFR-2 inhibitor, T-1-BHEPA [([Formula: see text]-[Formula: see text]-(4-(1-(2-benzoylhydrazono)ethyl)phenyl)-2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1[Formula: see text]-purin-1-yl)acetamide]. A structure-based computer-aided drug design (CADD) approach was employed, beginning with pharmacophore modeling, followed by in-depth computational validation. The binding affinity of T-1-BHEPA to VEGFR-2 was examined through molecular docking, 400 ns molecular dynamics (MD) simulations, MM-GBSA binding energy calculations, and protein–ligand interaction fingerprinting (ProLIF) interaction analysis, all of which confirmed a strong and stable interaction with the VEGFR-2 active site. DFT calculations indicated T-1-BHEPA’s stability and reactivity. Before semi-synthesis, in silico ADMET evaluations highlighted good solubility, nonhepatotoxicity, low CYP2D6 interaction and noncarcinogenic potential, along with a favorable chronic toxicity profile. Consistent with these predictions, T-1-BHEPA exhibited potent in vitro VEGFR-2 inhibition (IC 50 [Formula: see text] 0.059 ± 0.006 [Formula: see text]M), comparable to sorafenib (IC 50 [Formula: see text] 0.045 ± 0.006 [Formula: see text]M). T-1-BHEPA demonstrated selective cytotoxicity against a panel of cancer cell lines, with pronounced activity against MDA-MB-231 (IC 50 [Formula: see text] 11.64 ± 1.0 [Formula: see text]M), and a high selectivity index (SI > 6.7) over normal WI-38 cells. Cell cycle analysis revealed G2/M phase arrest, while apoptosis assays confirmed significant increases in early and late apoptotic populations. These effects were further supported by molecular markers, including elevated caspase-3, upregulation of Bax and downregulation of Bcl-2, consistent with activation of the intrinsic apoptotic pathway. Overall, T-1-BHEPA represents a rationally designed and biologically validated VEGFR-2 inhibitor with promising anticancer efficacy and safety, warranting further preclinical development.
Lassa fever hemorrhagic virus (LFHV) outbreaks in Nigeria continue to increase. With the possibility of a potentially deadly pandemic and the absence of a vaccine, an effective candidate drug that presents with no adverse effects and better clinical outcomes is urgently needed; hence, the aim of the study. Retrieved ligands: 5-(Methylene) evodiamine, N-(2-Fluorobenzoyl) evodiamine, N-[[2-(3-chlorophenyl)-5-(trifluoromethyl) pyrazol-3-yl]methyl]-2-(1-methyl-2,3-dihydroindol-5-yl) propanamide (NCTPMMDP), lauric acid, and sofosbuvir, and the target protein, 3MX5, were prepared and utilised for docking, molecular dynamics simulation, ADMET profiling, and DFT using standard protocols. The docking score for lauric acid was the lowest, with a value of - 6.1, followed by the standard drug and co-crystal control drug with scores of - 9.1 and - 8.9 kcal/mol, respectively. On the other hand, the scores of the other ligands ranged from - 9.5 to - 12.3 kcal/mol. Molecular simulations revealed fluctuations in the RMSD and RMSF values; however, overall, the formed complexes were stable during most of the docking simulation runs. Principal component analysis (PCA) analysis showed that all the ligands, apart from lauric acid, showed better conformational changes within the backbone of the protein. ADMET profiling showed that the ligands were better oral drug candidates than sofosbuvir, as revealed by their better absorption values and absolute compliance with the Lipinski rule of five. The DFT result showed that, apart from lauric acid, all the test ligands possess small energy gaps indicative of high reactivity. Put together, these findings indicate that the test ligands possess anti-LHFV potential that merits further in vivo and in vitro evaluations.
nucleocapsid proteinantiviral drug discoverysmall-molecule ligandsmolecular docking
Background: Kyasanur forest disease virus (KFDV) remains a significant public health challenge due to the limitations of existing vaccines, creating a critical need for effective antiviral treatments. KFDV is a tick-borne virus responsible for 400-500 new cases annually, with a mortality rate of 3-5%. The nonstructural protein 1 (NS1), which plays crucial roles in host cell interactions, immune evasion, and viral replication, represents a promising target for antiviral drug development. Objective: This study aims to identify potential antiviral compounds that inhibit the activity of KFDV NS1 protein using a computational pharmacological drug design approach. The objectives include determining the 3D structure of the NS1 protein through homology modeling, conducting virtual screening of phytochemicals to identify potential inhibitors, and performing molecular dynamics simulations to assess the stability and binding free energies of the selected compounds. Methods: The 3D structure of KFDV NS1 protein was predicted using homology modeling and validated using Ramachandran plot analysis. Virtual screening of phytochemicals from the Indian Medicinal Plants, Phytochemistry And Therapeutics (IMPPAT) database was performed to identify potential NS1 inhibitors. The top 15 compounds with the highest binding affinities were selected and subjected to absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis. Molecular dynamics simulations were conducted in duplicates for 200 ns to evaluate the stability of the ligand-NS1 complexes, and an additional independent simulation with randomized initial velocities was performed to ensure statistical robustness. Binding free energies were calculated using the molecular mechanics-generalized born surface area (MM-GBSA) method to determine the binding strength of each compound. Results: The 3D structure of the KFDV NS1 protein was determined using I-Tasser-MTD, Robetta, and Swiss Model servers, and a minimized model of I-Tasser, achieving an ERRAT score of 94.37, was selected. Virtual screening of 11,530 phytochemicals from the IMPPAT database identified the top 115 compounds after three screening phases. Out of the 15 screened compounds, L2, L3, and L5 demonstrated notable binding affinities of -9.34, -9.12, and -9.08 kcal/mol, respectively, compared to the FDA-approved antiviral dasabuvir, which had a binding affinity of -8.0 kcal/mol. Molecular dynamics simulations confirmed the stability of compounds L2 (IMPHY010294), L3 (IMPHY001281), L5 (IMPHY011162), and dasabuvir, with free-energy binding values of -62.97 ± 4.0, -77.22 ± 4.71, -62.07 ± 2.88, and -87.68 ± 4.31 kcal/mol, respectively. Conclusion: findings.
Kyasanur forest disease virusNS1 proteinantiviral drug designphytochemicals